HTBX - Heat Biologics hires advisory firm to support government collaborations

Heat Biologics (HTBX) is up ~9.0% in the premarket after the company announced that it has engaged CRS Crossroads Strategies, LLC, to assist in advancing government collaborations.With effect from February 01, CRS Crossroads, a bipartisan government relations firm based in Washington DC, will support Heat Biologics in its efforts to drive government collaborations related to COVID-19 and other vaccine programs.According to the regulatory filing, CRS’s expertise includes relationships with the members of the U.S. Congress and senior White House and Administration officials, including the HHS, BARDA (Biomedical Advanced Research and Development Authority), the CDC, and the FDA.Heat Biologics has a COVID-19 vaccine program based on its gp96 platform, which is currently in preclinical development.

For further details see:

Heat Biologics hires advisory firm to support government collaborations